Fig. 4From: Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCAChange from baseline in pre-bronchodilator FEV1 (mL). Mepolizumab 100 mg SC versus placebo. BMI body mass index, CI confidence interval, FEV1 forced expiratory volume in 1 s, SC subcutaneousBack to article page